Sino-US economic and trade consultations kick off tonight — which Chinese and American AI, trade, and biopharmaceutical companies could benefit?
- Core View: Expectations are rising for a new round of high-level Sino-US economic and trade consultations and a leaders' summit, which, combined with RMB appreciation, catalysts in the AI computing power chain, and the US plan to ease restrictions on Chinese innovative drug licensing deals, is creating a short-term trading window in the capital markets.
- Key Elements:
- He Lifeng will lead a delegation to visit the US from September 19 to 23, with the first consultation held in New York on September 20; the US side has confirmed that a state dinner will be hosted at the White House on September 24 to welcome the Chinese leader, forming a rhythm of "consultations building the framework + summit finalizing the list."
- Core topics cover AI security and technology export controls, tariff extensions, rare earth and critical mineral supply chains, and trade procurement lists; the market is watching whether the tariff truce set to expire on November 10 will be extended and what mechanism will be arranged for rare earth export controls.
- Chinese companies accompanying the delegation include industrial leaders such as BYD, Xiaomi, and CATL; US state dinner guests include Nvidia's Jensen Huang, OpenAI's Sam Altman, and Qualcomm's Cristiano Amon, with Apple's Tim Cook expected to attend.
- Since the news was released on September 17, the Nasdaq Golden Dragon China Index has risen 0.76%, outperforming the broader US stock market, with gains concentrated in Alibaba and the IDC computing power chain; on September 18, both the onshore and offshore RMB broke through 6.70, hitting a new high since February 2023.
- Beijing has issued the country's first provincial-level "Token Economy Ten Measures," and Morgan Stanley has raised its forecast for China's consumer-side AI monetizable revenue, providing independent logic support for the AI computing power chain.
- Reuters reported that the US Treasury Department is drafting new rules on pharmaceutical investment in China, aiming to preserve the ability of US companies to complete most Chinese drug licensing deals while restricting only areas involving pathogens or weaponizable biotechnology, with the amounts involved potentially reaching billions of dollars.
As a new round of high-level China-U.S. economic and trade consultations unfolds in New York, and expectations rise for a subsequent leaders' summit and a corporate delegation's visit to the U.S., capital markets are ushering in short-term trading catalysts. This article sorts out the key topics of this round of consultations, recent signals of capital maneuvering in the market, and the mapping of potential beneficiary sectors and targets such as the AI computing power chain, semiconductors, and innovative drugs.
1. Consultation Preview: From the New York Negotiating Table to the White House State Dinner
Economic and Trade Consultations: China's Ministry of Commerce announced on September 17 that Vice Premier He Lifeng would lead a delegation to visit the U.S. from September 19 to 23. The first round of consultations was held on the morning of September 20 local time at JPMorgan's headquarters in New York, with the U.S. side led by Treasury Secretary Bessent and joined by Trade Representative Greer. The two sides agreed to conduct dialogue guided by the important consensus of the two heads of state.
Leaders' Summit: The U.S. side has confirmed that it will host a state dinner at the White House on September 24 to welcome the Chinese leader. This is the second meeting between the two heads of state since May of this year. The rhythm of "forward-looking consultations building the framework + leaders' summit implementing the checklist" constitutes the core vehicle for current market expectations.
Core Negotiating Topics: The topics of this round of consultations are broader than before, covering AI and AI safety and technology export controls, tariff extension, rare earths and critical minerals supply chains, and trade procurement lists, among others. The market is focused on two hard indicators: whether the tariff truce expiring on November 10 this year can be further extended; and whether export controls on rare earths and critical minerals can form a more stable and predictable mechanism.
The lineup of participating and accompanying companies is strong: According to disclosures by Reuters and other media, the Chinese accompanying delegation is still being finalized but has already been revealed to include industry leaders such as BYD, Xiaomi, CATL, Gotion High-tech, Hisense, Wanxiang Group, as well as Bank of China and COFCO. Guests at the U.S. state dinner will include confirmed attendees such as Nvidia CEO Jensen Huang, OpenAI CEO Altman, and Qualcomm CEO Amon; Apple CEO Cook is also expected to attend.
2. Market and Exchange Rate Review: Signals of Early Positioning by Capital Markets
Since the Ministry of Commerce's announcement on September 17, Chinese concept stocks and the offshore RMB exchange rate have shown notably stronger characteristics.
Four Core Market Observations:
Chinese concept stocks significantly outperformed the broader U.S. market: Last Friday, the three major U.S. indices closed mixed (Dow -0.18%, S&P 500 +0.17%, Nasdaq +0.39%), while the Nasdaq Golden Dragon China Index surged 0.76%, with core assets such as Alibaba, Bilibili, and Pinduoduo generally rising against the trend.
Driven by the AI and cloud computing mainline, with clear structural divergence: Capital front-running showed structural characteristics, with gains highly concentrated in Alibaba and the IDC computing power chain (GDS, VNET), mainly driven by Alibaba's upcoming Apsara Conference and the resonance of the AI cycle, while consumer and e-commerce targets performed relatively flatly.
Significant RMB appreciation provides valuation support: On September 18, both the onshore and offshore RMB broke through the 6.70 mark against the dollar, hitting a new high since February 2023. Strong export growth and corporate foreign exchange settlement demand constitute the intrinsic support for the RMB exchange rate, which directly benefits the valuation elasticity of dollar-denominated Chinese concept stocks.
Domestic policy and foreign ratings create a positive resonance: Beijing released the country's first provincial-level "Token Economy Ten Measures," explicitly advancing the construction of "Token Factories"; meanwhile, Morgan Stanley raised its forecast for China's consumer-side AI monetizable revenue, providing independent logical support for the AI computing power chain.
3. What Chinese Concept Stocks Are Related to China's AI and Computing Power Chain
4. Other Positive News: U.S. Plans to Loosen Restrictions on Chinese Innovative Drug Licensing Deals
On September 18, Reuters cited three people familiar with the matter as reporting that the U.S. Treasury Department is drafting new rules on pharmaceutical investment in China, planning to preserve the ability of U.S. pharmaceutical companies to complete most Chinese drug licensing (license-in) deals, restricting them only when pathogens or weaponizable biotechnology are involved. The report said the framework is much looser than the position advocated by some members of Congress, and the amounts involved could reach the billions of dollars level.
What Are the Innovative Drug-Related Concept Stocks?
Disclaimer
This document is for general informational reference and market commentary purposes only. It is a compilation and analysis of public information and does not constitute any investment advice or recommendation, nor an offer or solicitation to buy or sell any securities or financial instruments, and does not take into account the investment objectives, financial situation, or specific needs of any particular recipient.
